ATHX) and Aspire Capital Fund, LLC (“Aspire Capital”) announced today that a new equity facility has been established, as a follow-on to a current facility. Under the new agreement, Athersys has the right to sell up to $100 million of its …
Athersys Inc. (ATHX) suffered a blow on Friday with the stock price dropping to a new 52-week low, on news that the primary and secondary endpoints of the company's phase II study of MultiStem cell therapy for treatment of ischemic …
Athersys, Inc. ATHX was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which …
A former custodian with stem cell developer Athersys (NASDAQ:ATHX) has been accused by federal prosecutors of running a stock scam that bilked would-be investors out of $340,000 over six years. Ronald Olear, 57, in some cases …
Athersys, Inc. (Nasdaq: ATHX) announced today that it has priced its offering of common stock. The Company has agreed to sell 19,802,000 shares of common stock through an underwritten public offering at $1.01 per share, which was the …
The offerings consisted of 7.5 million shares of common stock, which priced at $11.00 per share, and 16.5 million …
This is another stock that could provide investors a potential return in excess of 100% if the price target is hit. Cytomedix (CMXI), Athersys Inc. (NASDAQ: ATHX) and Titan Pharmaceuticals Inc. (TTNP) are all stocks that the PropThink team …
Regenerative medicine-focused biotech Athersys, Inc (NASDAQ:ATHX) put some vim into its share price with ... which was way ahead of the $3.72mln tipped by analysts that follow the stock. Shares rose 17% to $2.14 on the results. The …